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Abstract
 Purpose—A randomized controlled trial of cancer patients has linked early supportive care 
with improved hospice use and less aggressive end-of-life care. In practice, the early use of 
supportive interventions and potential impact on end-of-life care are poorly understood. We sought 
to describe early use of medications to treat common breast cancer symptoms (pain, insomnia, 
anxiety, and depression) and to assess the relationship between early use of these treatments and 
end-of-life care.
 Methods—Secondary analysis of 2006–2012 SEER-Medicare data. Women included had 
stage IV breast cancer and died within the observation period. We used modified Poisson 
regression to assess the relationship between supportive medication use in the 90 days post-
diagnosis and several end-of-life care measures (hospice use, in-hospital death, chemotherapy 
receipt within 14 days of death, ICU admission or >1 hospitalization or emergency department/ED 
visit 30 days before death).
 Results—Among the 947 women included, 68% of women used at least one supportive 
medication in the 90 days following their diagnosis: 60.3% used opioid pain medications, and 
28.3% received non-opioid psychotropic medications. Early use of any supportive medications 
was not associated with end-of-life care. Similarly, we found no differences in end-of-life care 
between opioid pain medication users and non-users. However, we found that non-opioid 
psychotropic medication users were less likely to receive chemotherapy in the last 14 days of life 
(aRR: 0.33, 95% CI: 0.12–0.88).
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 Conclusions—Non-opioid psychotropic use was associated with some aspects of end-of-life 
care. Future research should consider alternative measures of palliative and supportive care use 
using administrative data sources.
 Introduction
Integrating palliative care early in the course of treatment for patients with terminal cancer 
has gained attention in recent years as a promising strategy for improving patients’ quality of 
life (QOL)[1,2] and extending their survival.[3] In addition, early palliative care has been 
linked with measures of less aggressive end-of-life care. In a randomized controlled trial 
(RCT) of an early palliative care intervention, researchers found that patients who received 
early palliative care integrated with standard oncologic care were less likely than patients 
who received standard oncologic care alone to receive chemotherapy within 14 days of death 
and were more likely to transition to hospice prior to death.[4] One plausible hypothesis for 
the observed relationship between early palliative care, hospice use, and less intensive end-
of-life care is that, in providing decisional support, palliative care providers may assist both 
oncologists and patients in planning for the end of life. Such discussions may facilitate the 
transition from active treatment to palliative care and improve the quality of end of life care.
[4] As well, patients who receive palliative care, which emphasizes symptom control and 
quality of life, early in the cancer care trajectory may be more likely to prioritize quality of 
life and supportive over aggressive care throughout the treatment trajectory, including near 
the end of life.
Although patients, family members, and clinicians have expressed preferences for end-of-
life care that emphasizes pain relief and symptom management and preparation for dying,
[5–8] advanced cancer patients’ end-of-life care is increasingly aggressive. Over time, there 
has been an increase in the number of patients receiving multiple regimens of chemotherapy 
with ongoing administration near the end of life. Emergency department (ED) utilization and 
inpatient admissions in the final month of life are also rising.[9] Intensive end-of-life care is 
of questionable benefit in terms of lengthening life of terminally ill patients,[10] and may 
actually be detrimental to patients’ mental health and QOL[11,12] in addition to resulting in 
unnecessary health care expenditures.[13] As aggressive end-of-life care rises, hospice 
length has been decreasing, thus patients are not receiving the full benefit of hospice 
services.[9]
Early integration of palliative care services may be a promising strategy for improving 
quality of care at the end of life.[4] One key goal of palliative care interventions is to address 
symptoms and side effects of cancer and its treatment.[14,15] Pain, depression, anxiety, and 
sleeplessness are common symptoms that are often addressed pharmacologically.[16] It is 
unclear whether early use of medications to treat these symptoms could be an indicator of 
patients’ engagement with palliative care. Within a cohort of breast cancer patients, we 
sought to: (1) describe the early use of supportive medications to treat pain, depression, 
anxiety, and sleeplessness and (2) assess whether the early use of these symptom-directed 
therapies is associated with patients’ end-of-life care.
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 Methods
 Data Source
Data for this analysis came from the linkage of the National Cancer Institute’s Surveillance 
Epidemiology and End Result (SEER) database linked with Medicare fee-for-service 
administrative claims from 2006–2012. Medicare is a federal program that provides health 
insurance for persons age 65 and over in the United States. Approximately 97 percent of 
aged adults are eligible for Medicare.[17] The SEER program collects data from population-
based cancer registries, representing 28% of the population with cancer. The data are further 
linked with the National Death Index to obtain date and cause of death. For this study we 
utilized data from the prescription drug event (PDE) records, Medicare Provider Analysis 
and Review (MEDPAR) file for inpatient services, the Hospital Outpatient Standard 
Analytic file for outpatient facility services, 100% Physician/Supplier file for physicians’ 
services, and the Hospice file.[18]
 Cohort
We identified patients with a first diagnosis of breast cancer during 2007–2011 who were ≥ 
65 years old, and who were not diagnosed at autopsy or death and not missing month of 
diagnosis (N=104,629). From this group, we excluded patients who were not continuously 
enrolled in fee-for-service Medicare Parts A and B (inpatient and outpatient coverage, 
respectively) for 6 months before diagnosis and 3 months after diagnosis. We exclude 
patients enrolled in Medicare Advantage - privately managed health maintenance 
organization (HMO) plans – as we are unable to capture health care utilization for this 
subset of Medicare beneficiaries (n=40,875). We also excluded patients who were not 
enrolled in a stand-alone Medicare Part D plan for 3 months before and after diagnosis 
(n=30,105) as well as men (n=263) and women with end-stage renal disease (n=220). 
Finally, we excluded women diagnosed with stage 0, I, II, or III disease (n=31,767), those 
who were alive at the end of the study period (n=321), those who died within 90 days of 
diagnosis (n=108) and those who were enrolled in an HMO in the month before death 
(n=23). The final cohort consisted of 947 women.
 Outcomes
We created indicators for four end-of-life care measures that have been developed and 
measured in administrative data.[9,19] These were: 1) hospice use before death - including 
any use and the length of use among users; 2) terminal hospitalizations (in-hospital deaths); 
3) receipt of chemotherapy within 14 days of death; and 4) high-cost health care utilization 
(ICU admission, ≥1 emergency department visit, or ≥ 1 hospitalization) in the last 30 days of 
life.
 Independent Variable
The primary independent variable– early supportive medication use – was defined as use of 
a prescribed medication to treat depression, anxiety, insomnia, or pain within 90 days[3] of a 
patient’s breast cancer diagnosis. We identified relevant products using generic drug names 
in the Medicare Part D clams, including antidepressants, non-benzodiazepine anxiolytics 
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and sleep aids, and opioid analgesics (see Appendix 1 for included medications). We were 
unable to capture use of benzodiazepines, which may be used to treat anxiety and insomnia, 
as Medicare Part D did not cover the drugs during our study period.
 Control Variables
Covariates obtained from the SEER registry included age at diagnosis, race/ethnicity, marital 
status, year of diagnosis, and U.S. region of residence. Registry data also included the extent 
of urbanization at patients’ residences (from the Area Resource File), and 2000 census tract-
level measures of socioeconomic status, including median income and proportion of adult 
residents with <12 years of education. We assessed comorbid illness using the Klabunde 
modification of the Charlson score based on patients’ Medicare Part A and B claims during 
the 6-months before diagnosis.[20] Cancer-directed treatment variables (surgery, radiation, 
chemotherapy, endocrine therapy) were identified from inpatient, outpatient and pharmacy 
claims (Medicare Parts A, B and D) using International Classification of Diseases (ninth 
revision) (ICD9), Healthcare Common Procedure Coding System (HCPCS) codes and 
National Drug Codes (NDCs), respectively. We also controlled for patients’ history of any 
inpatient or outpatient mental health diagnosis (ICD9 codes 290.0–319.99), and prior use of 
the medications of interest.
 Propensity Score Estimation and Application
We estimated propensity-scores by modeling the probability of using supportive medications 
(any supportive medications, and individual categories of medications) in the 90 days 
following breast cancer diagnosis as a function of the control variables described above. 
Next, using the resulting propensity score, we created inverse probability of treatment 
weights (IPTW) for each patient; equal to 1/p (where p is the propensity score) for patients 
who used supportive medications and 1/(1−p) for patients who did not use supportive 
medications. We stabilized the propensity score weights by multiplying the IPTW weights 
by the marginal prevalence of the treatment actually received. This method of propensity 
score weighting provides an estimate of the treatment effect in the population (in this case, 
the effect of supportive medication use among stage IV breast cancer patients).[21]
 Statistical Analysis
We compared unadjusted baseline characteristics between patients grouped by early use of 
any supportive medications using Pearson chi-squared tests for categorical variables and 
Student t tests for continuous variables. Next, using the propensity score weighted cohort, 
we estimated the risk of each end-of-life care outcome for patients who received supportive 
medications versus those who did not. Separate models were estimated for 1) any supportive 
treatments, 2) opioid pain medications, and 3) non-opioid psychotropic medications 
(antidepressants/anxiolytics, non-benzodiazepine sleep aids). We examined use of opioid 
pain medications and non-opioid psychotropic medications separately because we expect 
that post-surgical and tumor-related pain management may be well integrated into standard 
oncologic care. Psychosocial symptom management with non-opioid psychotropic 
medications, on the other hand, may better indicate patients’ involvement with supportive 
care. Covariates that remained imbalanced among supportive treatment users and non-users 
after propensity score weighting were added to the outcome models as appropriate. We used 
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generalized estimating equations with log links and Poisson distributions to estimate 
adjusted risks and risk ratios with 95% confidence intervals for each outcome.[22] We used 
SAS 9.3 (Cary, NC) for all analyses.
 Sensitivity Analyses
We performed a sensitivity analysis to consider the effect of restricting the analytic sample 
to patients whose cause of death was listed as breast cancer. We also considered an 
alternative definition of supportive medication use that included use of antipsychotics, which 
may be used to treat depression.
 Results
There were 947 women who met our eligibility criteria. Mean and median survival from 
diagnosis was 634 (SD: 503) and 478 (IQR: 705) days, respectively. The mean age at 
diagnosis was 77 (SD: 7.6). Most patients were unmarried (widowed, divorced, or never 
married) (70.6%) and white (79.4%). About 85% of patients received treatment for their 
cancer: 24.6% had surgery, 34.6% received radiation, 60.3% received endocrine therapy, and 
43.9% received chemotherapy.
Approximately 68% of women used supportive medication in the 90 days following their 
diagnosis: 60.3% used opioid pain medications, and 28.3% received non-opioid 
psychotropic medications. Among those who received supportive medications, 20.6% of 
women used both opioids and non-opioid psychotropics. When comparing women who did 
and did not receive any supportive therapies prior to propensity score weighting, we found 
differences in age at diagnosis, marital status, region of residence, metropolitan versus non-
metropolitan residence, median census-tract income, previous mental health diagnosis, 
previous use of supportive medications, receipt of any cancer treatment, and receipt of 
surgery, radiation, and chemotherapy. After propensity score weighting, characteristics 
between the two groups were well balanced, with the exception of metropolitan versus non-
metropolitan residence (Table 1). Comparisons of women’s characteristics across three 
medication use groups (opioid pain medications, non-opioid psychotropic medications, 
neither type of medication) are displayed in Appendix 2.
In our sample, 68–69% of patients used hospice; 11% entered hospice within 3 days of 
death; 24–25% died in the hospital; 5% received chemotherapy within 14 days of death; and 
between 29–35% had an ICU admission, >1 ED visit, or >1 hospitalization in the last 30 
days of life. When considering all supportive treatments together (i.e., use of any supportive 
medications), we found no differences between medication users and non-users in terms of 
likelihood of experiencing any of the end-of-life care outcomes (Table 2).
When considering medication categories separately, in unadjusted analyses, opioid pain 
medication users had a 150% increased risk of receiving chemotherapy within 14 days of 
death, compared to patients who did not use opioid pain medications (RR: 2.50, 95%CI: 
1.26–4.97). In contrast, non-opioid psychotropic medication users had a 57% decreased risk 
of receiving chemotherapy within 14 days of death compared to patients who did not use 
these medications (RR: 0.43, 95% CI: 0.20–0.95) (Table 3).
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In adjusted analyses, there were few differences in end of life care by supportive medication 
use status. However, the relationship between non-opioid psychotropic use and receipt of 
chemotherapy within 14 days of death persisted with medication users having a 67% 
decreased risk of receiving chemotherapy within 14 days of death (aRR: 0.33, 95%CI: 0.12–
0.88). The risk of end-of-life chemotherapy receipt was 0.02 among non-opioid psychotropic 
users and 0.06 among non-users. Early use of opioid pain medications was no longer 
statistically significantly associated with receipt of chemotherapy at the end of life after 
adjustment.
In a sensitivity analysis restricting to patients who died of breast cancer (n=645), there were 
similarly no significant relationships between any supportive medication use or opioid pain 
medication use and end-of-life care measures. The effect of non-opioid psychotropic 
medication use on risk of receiving chemotherapy within 14 days of death became larger 
(aRR: 0.24, 95% CI: 0.06–0.95). Further, although there was no significant difference 
between non-opioid psychotropic users and non-users in risk of using hospice services, the 
relationship between non-opioid psychotropic use and risk of entering hospice within 3 days 
of death became marginally statistically significant (aRR: 0.39, 95% CI: 0.15–1.00). In an 
additional sensitivity analysis using an alternative definition of non-opioid psychotropic 
medication that included first and second generation anti-psychotics, results were consistent 
with our primary adjusted models.
 Discussion
Based on results from an RCT of an early palliative care intervention, we hypothesized that 
patients’ use of supportive medications may be associated with their end-of-life care. 
Overall, in our sample, use of any supportive medications was not associated with hospice 
use or intensity of end-of-life care. When considering medication groups separately, 
however, we found that non-opioid psychotropic medication use was associated with a 
decreased risk of receiving chemotherapy within 14 days of death. Across all analyses, we 
observed no significant relationships between early opioid pain medication use and end-of-
life care outcomes.
One possible explanation for our lack of an observed relationship between opioid pain 
medication use and end-of-life care is that pain management, compared to comprehensive 
supportive and psychosocial care, may be better integrated into standard oncologic care.
[23,24] In addition, a large proportion of opioid users in our sample appeared to be receiving 
these drugs post-surgery (among opioid users, nearly 30% had surgery). Opioid use for post-
surgical pain, in particular, may not be indicative of a patient’s engagement with other 
aspects of supportive care.
Receipt of non-opioid psychotropic medications that are often used to treat depression, 
anxiety, and sleeplessness may be a better indicator of a patient’s interaction with more 
comprehensive supportive care, and/or a provider serving in a supportive capacity (e.g., a 
mental health or primary care provider). If this is the case, patients receiving non-opioid 
psychotropic medications may also be more likely than non-recipients to receive decisional 
support and assistance in planning for the end of life. These aspects of supportive care may 
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help facilitate the transition from active treatment to palliative care,[4] although the results 
of our primary analysis did not suggest that non-opioid psychotropic medication use is 
associated with earlier or increased hospice use. We did find a reduced use of chemotherapy 
in the 14 days prior to death among non-opioid psychotropic users, which may indicate more 
intentional end-of-life care planning. Alternatively, this finding could also be the result of 
selection bias if, for example, if patients experiencing depression or anxiety are less 
motivated to continue cancer treatment.
Our lack of an observed relationship between supportive medication use and other aspects of 
end-of-life care, including hospice use and length of use, in our primary analysis could be 
because pharmacologic symptom management, although measurable in administrative 
claims data, is an insufficient indicator of patients’ engagement with supportive care. 
Although use of medications to treat pain and, in particular, depression, anxiety, and 
sleeplessness may reflect the involvement of mental health care and/or other supportive 
providers in patients’ cancer care, other aspects of supportive or palliative care that patients 
receive is likely highly variable.[25] The one study of an outpatient palliative care 
intervention that has demonstrated an effect on end-of-life care [4] included multiple 
components. In that RCT, although palliative care clinicians were allowed the flexibility to 
address individual patient needs, they were encouraged to follow palliative care visit 
guidelines adapted from the National Consensus Project for Quality Palliative Care.[26] 
Retrospective chart reviews from the trial revealed that palliative care consultations focused 
primarily on symptom management, patient and family coping, and illness understanding 
and education.[15] Apart from symptom management, these components of palliative care 
are difficult if not infeasible to measure using existing data sources. Thus, accurately 
capturing patients’ use of palliative care services in practice is challenging.
Interestingly, our sensitivity analyses did reveal a significant relationship between early use 
of non-opioid psychotropic medications and earlier hospice use when restricting to patients 
who died of their breast cancer. Women who died from cancer during the study period might 
have distinct supportive care needs and may benefit the most from both symptom 
management and advance care planning aspects of supportive care. This may explain why, in 
this sample, patients who used non-opioid psychotropics were less likely to enter hospice 
very near death. This may also explain why the negative effect of non-opioid psychotropic 
use on risk of receiving chemotherapy within 14 days of death was larger in this restricted 
sample than in our main analysis.
The interpretation of our findings is limited by a number of factors. The first concerns 
external generalizability, as our study was limited to fee-for-service Medicare beneficiaries 
with advanced breast cancer; excluding patients enrolled in Medicare HMO plans. However, 
fee-for-service enrollees represent over 70% of all Medicare Beneficiaries during our study 
period.[27]
It is unclear whether our findings extend to patients with other cancers and/or other (or no) 
insurance coverage. Second, following previous studies,[3] our measures of early supportive 
care consisted of binary indicators of medication use in the 90 days following breast cancer 
diagnosis. Thus, we did not capture the specific timing or intensity of patients’ use of 
Check et al. Page 7
Support Care Cancer. Author manuscript; available in PMC 2017 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
supportive services. Third, we likely underestimated use of non-opioid psychotropic 
medications as we were unable to capture use of benzodiazepines, which may be used to 
treat anxiety and insomnia. Medicare Part D did not cover Benzodiazepines until 2013, after 
our study period. Fourth, we were unable to control for unmeasured patient-level factors that 
may confound the relationship between early supportive medication use and different 
aspects of end-of-life care. Thus, we cannot infer causality from our observed relationships 
between medication use and some aspects of end-of-life care. Finally, it is important to note 
that our study and others that do not account for patients’ and caregivers’ preferences for and 
experiences with end-of-life care cannot draw conclusions about quality of end-of-life care.
Our study expands upon existing RCT evidence about the role of early supportive cancer 
care by providing novel observational data about the early use of medications to control 
symptoms in practice, and the relationship between use of these services and patterns of care 
at the end of life. Specifically, our study found that women who received non-opioid 
psychotropic medications had a decreased risk of receiving chemotherapy within 14 days of 
death. In the context of increasingly aggressive EOL care that may be inconsistent with 
patients’ preferences in general,[5–8, 28] the results of our study and others suggest that 
early engagement with supportive care may be a promising strategy for reducing 
aggressiveness of care very near death. However, assessing whether less aggressive care at 
the end of life is consistent with good quality care requires the inclusion of data on patients’ 
and caregivers’ specific preferences for and experiences with EOL care. Future research 
should also consider alternative measures of palliative and supportive care use using 
administrative and other data sources. For example, it may be possible to isolate opioid use 
not related to surgery by restricting the dates on which opioid prescriptions were filled to 
those not proximate to surgery. Separate from supportive medication use, researchers might 
consider measuring claims for services provided by non-oncology providers who may serve 
in a supportive capacity (e.g., primary care or mental health providers). Encounters for 
patient counseling and decision support are also important aspects of supportive care, 
however, such encounters may be under-coded in claims data and better captured by clinical 
records.
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 Appendix 1. Sample characteristics by use of opioid pain medications 
and non-opioid psychotropic medications, before propensity score 
weighting
Opioid pain medications Non-opioid psychotropic medications
Non-Users Users p-value Non-Users Users p-value
Number of Patients 376 571 679 268
Demographic Characteristics
Age at Cancer Diagnosis – Mean (SD) 78.99 75.95 <0.0001 77.32 76.74 0.2881
Marital Status at Diagnosis, % 
Married/Partnered
20.48 237.67 <0.05 24.74 25.00 0.9208
Race
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Opioid pain medications Non-opioid psychotropic medications
Non-Users Users p-value Non-Users Users p-value
 White 78.72 79.86 0.6722 75.85 88.43 <0.0001
 Non-White 21.28 20.14 24.15 11.57
Hispanic Ethnicity
 Yes 7.18 8.06 0.0844 8.25 6.34 0.6128
 No 92.82 90.72 91.02 92.91
Median Household Income in Census 
Tract of Residence
 $5,299 – 26,387 19.41 28.37 0.9232 24.01 26.87 0.3615
 $26,388 – 36,095 22.07 27.15 26.07 22.76
 $36,096 – 50,560 27.93 22.94 25.33 23.88
 $50,561 – 200,014 48.10 51.90 24.59 26.12
Proportion of Residents with No High 
School Degree in Census Tract of 
Residence
 0.53 – 8.98% 26.33 23.64 <0.05 23.56 27.61 0.0944
 8.99 – 16.50% 28.99 22.77 27.25 20.15
 16.51 – 27.60% 23.40 25.92 24.59 25.75
 27.61 – 79.99% 21.01 27.67 24.59 26.12
Residence
 Metropolitan County 86.70 77.76 <0.001 81.59 80.60 0.7239
 Non-Metropolitan County 13.30 22.24 18.41 19.40
U.S. Region
 Northeast 33.24 19.61 <0.0001 27.39 19.03 <0.05
 Midwest 14.63 15.06 15.32 23.81
 South 33.24 34.33 33.28 35.45
 West 18.88 31.00 24.01 31.72
Clinical Characteristics
Year of Cancer Diagnosis
 2007 28.72 21.37 0.1086 25.33 21.64 0.5506
 2008 18.35 22.27 20.47 22.39
 2009 20.21 21.89 21.21 21.27
 2010 17.55 18.39 17.08 20.52
 2011 15.16 15.59 15.91 14.18
Charlson Comorbidity Score
 0 75.53 68.13 0.05 75,26 60.45 <0.0001
 1 17.02 21.89 17.23 26.87
 2+ 7.45 9.98 7.51 12.69
Cancer Treatment (Any) 81.12 87.57 <0.01 84.98 85.07 0.9700
 Surgery 18.62 28.55 <0.001 23.56 27.24 0.2369
 Radiation 29.26 38.18 <0.01 36.67 29.48 0.0361
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Opioid pain medications Non-opioid psychotropic medications
Non-Users Users p-value Non-Users Users p-value
 Chemotherapy 37.23 48.34 <0.001 44.48 42.54 0.5879
 Endocrine Therapy 60.64 60.07 0.8612 59.94 61.19 0.7226
Previous Mental Health Diagnosis 16.49 16.64 0.9522 10.31 32.46 <0.0001
Previous Supportive Medication Use 
(Any)
23.94 42.38 <0.0001 20.77 71.27 <0.0001
 Previous Opioid Use 8.78 31.35 <0.0001 17.67 34.33 <0.0001
 Previous Non-Opioid Psychotropic 
Use
17.02 23.47 <0.05 4.42 62.69 <0.0001
a43 patients were missing information on marital status at diagnosis; 7 were missing information on Hispanic ethnicity; 1 
was missing census tract information; dummy variables were included in the models so that these patients were not 
excluded from analyses.
bValues in bold are statistically significant c The “Black” and “Other Race” categories were collapsed for the purposes of 
the table to protect patients’ identities
 Appendix 2. Generic Names of Medications Included in Analysis
Supportive Medication Category Generic Drug Names
Opioid Pain Medications
Buprenorphine
Fentanyl
Hydrocodone
Hydromorphone
Levorphanol
Meperidine
Methadone
Morphine
Nalbuphine
Oxycodone
Oxymorphone
Propoxyphene
Tapentadol
Tramadol
Non-Opioid Psychotropic Medications
Antidepressants:
Amitriptyline
Amoxapine
Bupropion
Citalopram
Clomipramine
Desipramine
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Supportive Medication Category Generic Drug Names
Desvenlafaxine
Doxepin
Duloxetine
Escitalopram
Fluoxetine
Fluvoxamine
Imipramine
Isocarboxazid
Maprotiline
Milnacipran
Mirtazapine
Nefazodone
Nortriptyline
Paroxetine
Phenelzine
Protryptyline
Sertraline
Tranylcypromine
Trazodone
Trimipramine
Venlafaxine
Vilazodone
Non-benzodiazepine sleep aids:
Hydroxyzine
Pregabalin
Buspirone
Zolpidem
Eszopiclone
Zaleplon
Antipsychotics:
Apriprazole
Asenapine
Chlorpromazine
Clozapine
Fluphenazine
Haloperidol
Iloperidone
Loxapine
Lurasidone
Olanzapine
Paliperidone
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Supportive Medication Category Generic Drug Names
Perphenazine
Pimozide
Quetiapine
Risperidone
Thiothixene
Trifluoperazine
Ziprasadone
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